RxDoctor Payments Data

Manmohan Katapadi, MD

Cardiovascular Disease · Columbus, OHNPI 1528192820

Payments from drug & device makers

$123,800in general payments, 2019–2025

Across 1,115 payments — averaging $111.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$54K
  • Esperion Therapeutics, Inc.$34K
  • Novartis$10K
  • AstraZeneca$8K
  • Boehringer Ingelheim$5K
  • Merck$3K
  • plus $10K from 43 others

What the payments were for

  • Consulting fees$6,2105%
  • Speaking & faculty fees$89,70172%
  • Travel & lodging$8,0306%
  • Food & beverage$19,20416%
  • Education$6551%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$123,800 in reported general payments places this provider in the 90th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$196,021
Medicare patients
388
Services billed
2,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan236$254,231
EliquisApixaban172$180,103
JardianceEmpagliflozin85$89,962
XareltoRivaroxaban82$84,569
Repatha SureclickEvolocumab51$39,059
VascepaIcosapent Ethyl52$37,500
MultaqDronedarone Hcl29$34,966
FarxigaDapagliflozin Propanediol25$32,008
NexlizetBempedoic Acid/Ezetimibe23$17,412
OzempicSemaglutide12$11,244
Ranolazine ErRanolazine98$10,482
Tadalafil17$8,926
VerquvoVericiguat13$8,398
Dabigatran EtexilateDabigatran Etexilate Mesylate23$7,366
Dofetilide30$7,151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$10,321$254,231236 claims
PfizerEliquis$521$180,103172 claims
Boehringer IngelheimJardiance$4,921$89,96285 claims
Johnson & JohnsonXarelto$1,463$84,56982 claims
Sanofi-aventis U.S. LLCMultaq$906$34,96629 claims
AstraZenecaFarxiga$7,568$32,00825 claims
Esperion Therapeutics, Inc.Nexlizet$33,758$17,41223 claims
Novo NordiskOzempic$224$11,24412 claims
MerckVerquvo$3,300$8,39813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →